Spyre Therapeutics
SYRE
SYRE
71 hedge funds and large institutions have $154M invested in Spyre Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
-6
Holders Change %
-7.79%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
6
Increased
24
Reduced
22
Closed
11
Calls
$19K
Puts
$1K
Net Calls
+$18K
Net Calls Change
+$19K
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$5.38M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.17M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.09M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$520K |
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.49M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$1.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.28M |
| 4 |
Millennium Management
New York
|
-$520K |
| 5 |
Man Group
London,
United Kingdom
|
-$389K |
